Shares of Scancell Holdings plc (LON:SCLP – Get Free Report) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 13.76 ($0.17) and traded as low as GBX 9.50 ($0.12). Scancell shares last traded at GBX 10.10 ($0.12), with a volume of 844,442 shares trading hands.
Scancell Stock Performance
The company has a fifty day moving average price of GBX 12.24 and a two-hundred day moving average price of GBX 13.73. The company has a market capitalization of £93.89 million, a P/E ratio of -1,010.00 and a beta of 0.35. The company has a debt-to-equity ratio of 61.41, a current ratio of 3.42 and a quick ratio of 13.01.
Scancell Company Profile
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Scancell
- Investing in the High PE Growth Stocks
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- Canadian Penny Stocks: Can They Make You Rich?
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
